Alyeska Investment Group, L.P. Biogen Inc. Transaction History

Alyeska Investment Group, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $44.6 Million - $55.5 Million	234,312 Added 140.56%	401,005 $93 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $54.3 Million - $68.5 Million	-255,987 Reduced 60.56%	166,693 $35.9 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $12.3 Million - $14.8 Million	55,412 Added 15.09%	422,680 $109 Million
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $101 Million - $117 Million	367,268 New	367,268 $105 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $6.33 Million - $7.69 Million	25,064 New	25,064 $6.94 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $16.9 Million - $27.1 Million	65,367 New	65,367 $22.6 Million

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.